|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...8687888990919293949596...9899» |
- tegafur/uracil / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Metastases: Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE (clinicaltrials.gov) - Mar 28, 2012
P2, N=143, Recruiting, Sponsor: Egyptian Society of Liver Cancer
Active, not recruiting --> Recruiting
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, Isentress (raltegravir) / Merck (MSD)
New P1/2 trial: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. (clinicaltrials.gov) - Mar 27, 2012
P1/2, N=52, Completed, Sponsor: Gilead Sciences
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
New P3 trial: Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition (clinicaltrials.gov) - Mar 26, 2012
P3, N=20, Recruiting, Sponsor: Johane Allard
- New P2 trial: Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis (clinicaltrials.gov) - Mar 26, 2012
P2, N=30, Recruiting, Sponsor: Gachon University Gil Medical Center
- Enrollment change, HEOR: MHE: Study of Lactulose in Children With Chronic Liver Disease (clinicaltrials.gov) - Mar 25, 2012
P2, N=16, Terminated, Sponsor: Indiana University
Active, not recruiting --> Recruiting N=50 --> 16
- tacrolimus intravenous / Generic mfg.
Preclinical: TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=86, Recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial termination, Monotherapy: Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) (clinicaltrials.gov) - Mar 25, 2012
P3, N=261, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=50 --> 16 Completed --> Terminated; This study was terminated due to low enrollment
- | Exviera (dasabuvir) / AbbVie
New P2 trial: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects (clinicaltrials.gov) - Mar 25, 2012
P2, N=12, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | bardoxolone methyl (RTA 402) / Kyowa Kirin, Biogen
New P1 trial: Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - Mar 25, 2012
P1, N=34, Completed, Sponsor: Reata Pharmaceuticals, Inc.
- ||| Ledipasvir (GS-5885) / Gilead
Trial completion: A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (clinicaltrials.gov) - Mar 25, 2012
P1, N=71, Completed, Sponsor: Gilead Sciences
Completed --> Terminated; This study was terminated due to low enrollment Active, not recruiting --> Completed
- || Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment change: Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) (clinicaltrials.gov) - Mar 22, 2012
P1, N=177, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=60 --> 177
- ||| entecavir / Generic mfg.
Enrollment change: Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - Mar 21, 2012
P4, N=131, Completed, Sponsor: Bristol-Myers Squibb
N=60 --> 177 N=80 --> 131
- |||| Vanihep (vaniprevir) / Merck (MSD)
Trial completion: A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) (clinicaltrials.gov) - Mar 21, 2012
P2, N=90, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=80 --> 131 Active, not recruiting --> Completed
- | orantinib (TSU-68) / Otsuka, Pfizer
Trial completion, P1/2 data, Metastases: Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 21, 2012
P1/2, N=35, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Trial termination, Metastases: Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) (clinicaltrials.gov) - Mar 21, 2012
P2, N=33, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Completed --> Terminated
- | Trial initiation date: Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis (clinicaltrials.gov) - Mar 21, 2012
P3, N=73, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Completed --> Terminated Initiation date: Jan 2005 --> Jul 2005
- | Enrollment change: Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis (clinicaltrials.gov) - Mar 21, 2012
P3, N=73, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Initiation date: Jan 2005 --> Jul 2005 N=100 --> 73
- |||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Combination therapy: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV (clinicaltrials.gov) - Mar 21, 2012
P2, N=62, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
N=100 --> 73 Active, not recruiting --> Completed
- Travelan (IMM-124E) / Immuron
Trial initiation date: Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis (clinicaltrials.gov) - Mar 20, 2012
P2, N=0, Withdrawn, Sponsor: Immuron Ltd.
Active, not recruiting --> Completed Initiation date: Feb 2012 --> Dec 2012
- ITX-5061 / iTherX
New P1 trial: Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection (clinicaltrials.gov) - Mar 20, 2012
P1, N=10, Recruiting, Sponsor: Schiano, Thomas D., MD
- melphalan / Generic mfg.
Trial completion, Metastases: Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases (clinicaltrials.gov) - Mar 20, 2012
P2, N=67, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Initiation date: Feb 2012 --> Dec 2012 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 20, 2012
P1, N=108, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P4 trial: Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy (clinicaltrials.gov) - Mar 19, 2012
P4, N=20, Completed, Sponsor: University of Roma La Sapienza
- | ribavirin / Generic mfg.
New P2 trial, Pre-transplantation, Post-transplantation: Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant (clinicaltrials.gov) - Mar 19, 2012
P2, N=50, Active, not recruiting, Sponsor: Gilead Sciences
- Enrollment closed: Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy (clinicaltrials.gov) - Mar 18, 2012
P=N/A, N=140, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- metformin hydrochloride extended release / Generic mfg.
Enrollment closed: Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Mar 18, 2012
P4, N=66, Active, not recruiting, Sponsor: Manal Abdelmalek
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Pegasys (pegylated interferon α -2a) / Roche
Enrollment change: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) (clinicaltrials.gov) - Mar 15, 2012
P=N/A, N=1155, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=314 --> 1155
- ||| tolvaptan / Generic mfg.
New P3 trial, HEOR: Effect of Tolvaptan on Cognitive Function in Cirrhosis (clinicaltrials.gov) - Mar 14, 2012
P3, N=25, Completed, Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center
- ||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment change: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive (clinicaltrials.gov) - Mar 13, 2012
P4, N=265, Completed, Sponsor: Hoffmann-La Roche
N=314 --> 1155 N=176 --> 265
- Trial completion: LiF-Pro: Dietary Protein and Hepatic Fat Accumulation (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=29, Completed, Sponsor: Wageningen University
N=176 --> 265 Recruiting --> Completed
- ||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
Enrollment open: Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=850, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment closed, Combination therapy: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care (clinicaltrials.gov) - Mar 13, 2012
P2, N=120, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | pegylated recombinant human arginase (BCT-100) / BCT international
Enrollment change, Metastases: Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) (clinicaltrials.gov) - Mar 12, 2012
P1/2, N=20, Completed, Sponsor: Bio-Cancer Treatment International Limited
Recruiting --> Active, not recruiting N=50 --> 20
- Enrollment closed: Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection (clinicaltrials.gov) - Mar 12, 2012
P2, N=110, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=50 --> 20 Recruiting --> Active, not recruiting
- | pegylated recombinant human arginase (BCT-100) / BCT international
Trial completion, Metastases: Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) (clinicaltrials.gov) - Mar 12, 2012
P1/2, N=20, Completed, Sponsor: Bio-Cancer Treatment International Limited
Recruiting --> Active, not recruiting Recruiting --> Completed
- pegylated recombinant human arginase (BCT-100) / BCT international
Enrollment change, Metastases: Study of Pegylated Human Recombinant Arginase for Liver Cancer (clinicaltrials.gov) - Mar 12, 2012
P1, N=15, Completed, Sponsor: Bio-Cancer Treatment International Limited
Recruiting --> Completed N=42 --> 15
- New P1 trial: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002) (clinicaltrials.gov) - Mar 12, 2012
P1, N=37, Terminated, Sponsor: Merck
- ALS-2158 / J&J, Vertex
New P1 trial: First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Mar 12, 2012
P1, N=78, Terminated, Sponsor: Alios Biopharma Inc.
- Enrollment open: Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=238, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=42 --> 15 Not yet recruiting --> Recruiting
- | pegylated recombinant human arginase (BCT-100) / BCT international
Trial completion, Metastases: Study of Pegylated Human Recombinant Arginase for Liver Cancer (clinicaltrials.gov) - Mar 12, 2012
P1, N=15, Completed, Sponsor: Bio-Cancer Treatment International Limited
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change, Surgery: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=30, Completed, Sponsor: Pathfinder Therapeutics
Recruiting --> Completed N=20 --> 30
- Enrollment change, Surgery: Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=27, Completed, Sponsor: Pathfinder Therapeutics
N=20 --> 30 N=20 --> 27
- | Trial completion, Surgery: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=30, Completed, Sponsor: Pathfinder Therapeutics
N=20 --> 27 Recruiting --> Completed
- | Trial completion, Surgery: Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=27, Completed, Sponsor: Pathfinder Therapeutics
Recruiting --> Completed Recruiting --> Completed
- Pegasys (pegylated interferon α -2a) / Roche
Trial completion: DARGEN-3: High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (clinicaltrials.gov) - Mar 11, 2012
P4, N=101, Completed, Sponsor: Dr. Conrado Fernandez
Recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial initiation date, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Mar 7, 2012
P2, N=40, Recruiting, Sponsor: McGill University Health Center
Active, not recruiting --> Completed Initiation date: Dec 2010 --> Dec 2011
- Isentress (raltegravir) / Merck (MSD)
Enrollment open, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Mar 7, 2012
P2, N=40, Recruiting, Sponsor: McGill University Health Center
Initiation date: Dec 2010 --> Dec 2011 Not yet recruiting --> Recruiting
- ornithine phenylacetate oral (MNK-6106) / Mallinckrodt
New P2 trial: STOP-ALF: Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury (clinicaltrials.gov) - Mar 6, 2012
P2, N=24, Recruiting, Sponsor: William Lee
- | golotimod (SCV 07) / SciClone
Trial completion: Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=12, Completed, Sponsor: SciClone Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Biomarker, Trial termination: Selenium Supplementation of Patients With Cirrhosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=99, Terminated, Sponsor: Vanderbilt University
Recruiting --> Completed Recruiting --> Terminated; Insufficient funds to complete study.